A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance

Research output: Contribution to journalReviewResearchpeer-review

Standard

A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance. / Mudhar, Hardeep Singh; Krishna, Yamini; Cross, Simon; Auw-Haedrich, Claudia; Barnhill, Raymond; Cherepanoff, Svetlana; Eagle, Ralph; Farmer, James; Folberg, Robert; Grossniklaus, Hans; Herwig-Carl, Martina C.; Hyrcza, Martin; Lassalle, Sandra; Loeffler, Karin U.; Moulin, Alexandre; Milman, Tatyana; Verdijk, Robert M.; Heegaard, Steffen; Coupland, Sarah E.

In: Laboratory investigation; a journal of technical methods and pathology, Vol. 104, No. 1, 100281, 2024.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Mudhar, HS, Krishna, Y, Cross, S, Auw-Haedrich, C, Barnhill, R, Cherepanoff, S, Eagle, R, Farmer, J, Folberg, R, Grossniklaus, H, Herwig-Carl, MC, Hyrcza, M, Lassalle, S, Loeffler, KU, Moulin, A, Milman, T, Verdijk, RM, Heegaard, S & Coupland, SE 2024, 'A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance', Laboratory investigation; a journal of technical methods and pathology, vol. 104, no. 1, 100281. https://doi.org/10.1016/j.labinv.2023.100281

APA

Mudhar, H. S., Krishna, Y., Cross, S., Auw-Haedrich, C., Barnhill, R., Cherepanoff, S., Eagle, R., Farmer, J., Folberg, R., Grossniklaus, H., Herwig-Carl, M. C., Hyrcza, M., Lassalle, S., Loeffler, K. U., Moulin, A., Milman, T., Verdijk, R. M., Heegaard, S., & Coupland, S. E. (2024). A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance. Laboratory investigation; a journal of technical methods and pathology, 104(1), [100281]. https://doi.org/10.1016/j.labinv.2023.100281

Vancouver

Mudhar HS, Krishna Y, Cross S, Auw-Haedrich C, Barnhill R, Cherepanoff S et al. A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance. Laboratory investigation; a journal of technical methods and pathology. 2024;104(1). 100281. https://doi.org/10.1016/j.labinv.2023.100281

Author

Mudhar, Hardeep Singh ; Krishna, Yamini ; Cross, Simon ; Auw-Haedrich, Claudia ; Barnhill, Raymond ; Cherepanoff, Svetlana ; Eagle, Ralph ; Farmer, James ; Folberg, Robert ; Grossniklaus, Hans ; Herwig-Carl, Martina C. ; Hyrcza, Martin ; Lassalle, Sandra ; Loeffler, Karin U. ; Moulin, Alexandre ; Milman, Tatyana ; Verdijk, Robert M. ; Heegaard, Steffen ; Coupland, Sarah E. / A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance. In: Laboratory investigation; a journal of technical methods and pathology. 2024 ; Vol. 104, No. 1.

Bibtex

@article{4ca78f2e945c46eea7da53ba551199b6,
title = "A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance",
abstract = "Several nomenclature and grading systems have been proposed for conjunctival melanocytic intraepithelial lesions (C-MIL). The fourth {"}WHO Classification of Eye Tumors{"} (WHO-EYE04) proposed a C-MIL classification, capturing the progression of noninvasive neoplastic melanocytes from low- to high-grade lesions, onto melanoma in situ (MIS), and then to invasive melanoma. This proposal was revised to the WHO-EYE05 C-MIL system, which simplified the high-grade C-MIL, whereby MIS was subsumed into high-grade C-MIL. Our aim was to validate the WHO-EYE05 C-MIL system using digitized images of C-MIL, stained with hematoxylin and eosin and immunohistochemistry. However, C-MIL cases were retrieved from 3 supraregional ocular pathology centers. Adequate conjunctival biopsies were stained with hematoxylin and eosin, Melan-A, SOX10, and PReferentially expressed Antigen in Melanoma. Digitized slides were uploaded on the SmartZoom platform and independently scored by 4 ocular pathologists to obtain a consensus score, before circulating to 14 expert eye pathologists for independent scoring. In total, 105 cases from 97 patients were evaluated. The initial consensus diagnoses using the WHO-EYE04 C-MIL system were as follows: 28 benign conjunctival melanoses, 13 low-grade C-MIL, 37 high-grade C-MIL, and 27 conjunctival MIS. Using this system resulted in 93% of the pathologists showing only fair-to-moderate agreement (kappa statistic) with the consensus score. The WHO-EYE05 C-MIL system (with high-grade C-MIL and MIS combined) improved consistency between pathologists, with the greatest level of agreement being seen with benign melanosis (74.5%) and high-grade C-MIL (85.4%). Lowest agreements remained between pathologists for low-grade C-MIL (38.7%). Regarding WHO-EYE05 C-MIL scoring and clinical outcomes, local recurrences of noninvasive lesions developed in 8% and 34% of the low- and high-grade cases. Invasive melanoma only occurred in 47% of the cases that were assessed as high-grade C-MIL. This extensive international collaborative study is the first to undertake a comprehensive review of the WHO-EYE05 C-MIL scoring system, which showed good interobserver agreement and reproducibility.",
keywords = "conjunctival melanoma, conjunctival melanoma in situ, digital pathology, high-grade conjunctival melanocytic intraepithelial lesions, immunohistochemistry, low-grade conjunctival melanocytic intraepithelial lesions",
author = "Mudhar, {Hardeep Singh} and Yamini Krishna and Simon Cross and Claudia Auw-Haedrich and Raymond Barnhill and Svetlana Cherepanoff and Ralph Eagle and James Farmer and Robert Folberg and Hans Grossniklaus and Herwig-Carl, {Martina C.} and Martin Hyrcza and Sandra Lassalle and Loeffler, {Karin U.} and Alexandre Moulin and Tatyana Milman and Verdijk, {Robert M.} and Steffen Heegaard and Coupland, {Sarah E.}",
note = "Publisher Copyright: Copyright {\textcopyright} 2023 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2024",
doi = "10.1016/j.labinv.2023.100281",
language = "English",
volume = "104",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - A Multicenter Study Validates the WHO 2022 Classification for Conjunctival Melanocytic Intraepithelial Lesions With Clinical and Prognostic Relevance

AU - Mudhar, Hardeep Singh

AU - Krishna, Yamini

AU - Cross, Simon

AU - Auw-Haedrich, Claudia

AU - Barnhill, Raymond

AU - Cherepanoff, Svetlana

AU - Eagle, Ralph

AU - Farmer, James

AU - Folberg, Robert

AU - Grossniklaus, Hans

AU - Herwig-Carl, Martina C.

AU - Hyrcza, Martin

AU - Lassalle, Sandra

AU - Loeffler, Karin U.

AU - Moulin, Alexandre

AU - Milman, Tatyana

AU - Verdijk, Robert M.

AU - Heegaard, Steffen

AU - Coupland, Sarah E.

N1 - Publisher Copyright: Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2024

Y1 - 2024

N2 - Several nomenclature and grading systems have been proposed for conjunctival melanocytic intraepithelial lesions (C-MIL). The fourth "WHO Classification of Eye Tumors" (WHO-EYE04) proposed a C-MIL classification, capturing the progression of noninvasive neoplastic melanocytes from low- to high-grade lesions, onto melanoma in situ (MIS), and then to invasive melanoma. This proposal was revised to the WHO-EYE05 C-MIL system, which simplified the high-grade C-MIL, whereby MIS was subsumed into high-grade C-MIL. Our aim was to validate the WHO-EYE05 C-MIL system using digitized images of C-MIL, stained with hematoxylin and eosin and immunohistochemistry. However, C-MIL cases were retrieved from 3 supraregional ocular pathology centers. Adequate conjunctival biopsies were stained with hematoxylin and eosin, Melan-A, SOX10, and PReferentially expressed Antigen in Melanoma. Digitized slides were uploaded on the SmartZoom platform and independently scored by 4 ocular pathologists to obtain a consensus score, before circulating to 14 expert eye pathologists for independent scoring. In total, 105 cases from 97 patients were evaluated. The initial consensus diagnoses using the WHO-EYE04 C-MIL system were as follows: 28 benign conjunctival melanoses, 13 low-grade C-MIL, 37 high-grade C-MIL, and 27 conjunctival MIS. Using this system resulted in 93% of the pathologists showing only fair-to-moderate agreement (kappa statistic) with the consensus score. The WHO-EYE05 C-MIL system (with high-grade C-MIL and MIS combined) improved consistency between pathologists, with the greatest level of agreement being seen with benign melanosis (74.5%) and high-grade C-MIL (85.4%). Lowest agreements remained between pathologists for low-grade C-MIL (38.7%). Regarding WHO-EYE05 C-MIL scoring and clinical outcomes, local recurrences of noninvasive lesions developed in 8% and 34% of the low- and high-grade cases. Invasive melanoma only occurred in 47% of the cases that were assessed as high-grade C-MIL. This extensive international collaborative study is the first to undertake a comprehensive review of the WHO-EYE05 C-MIL scoring system, which showed good interobserver agreement and reproducibility.

AB - Several nomenclature and grading systems have been proposed for conjunctival melanocytic intraepithelial lesions (C-MIL). The fourth "WHO Classification of Eye Tumors" (WHO-EYE04) proposed a C-MIL classification, capturing the progression of noninvasive neoplastic melanocytes from low- to high-grade lesions, onto melanoma in situ (MIS), and then to invasive melanoma. This proposal was revised to the WHO-EYE05 C-MIL system, which simplified the high-grade C-MIL, whereby MIS was subsumed into high-grade C-MIL. Our aim was to validate the WHO-EYE05 C-MIL system using digitized images of C-MIL, stained with hematoxylin and eosin and immunohistochemistry. However, C-MIL cases were retrieved from 3 supraregional ocular pathology centers. Adequate conjunctival biopsies were stained with hematoxylin and eosin, Melan-A, SOX10, and PReferentially expressed Antigen in Melanoma. Digitized slides were uploaded on the SmartZoom platform and independently scored by 4 ocular pathologists to obtain a consensus score, before circulating to 14 expert eye pathologists for independent scoring. In total, 105 cases from 97 patients were evaluated. The initial consensus diagnoses using the WHO-EYE04 C-MIL system were as follows: 28 benign conjunctival melanoses, 13 low-grade C-MIL, 37 high-grade C-MIL, and 27 conjunctival MIS. Using this system resulted in 93% of the pathologists showing only fair-to-moderate agreement (kappa statistic) with the consensus score. The WHO-EYE05 C-MIL system (with high-grade C-MIL and MIS combined) improved consistency between pathologists, with the greatest level of agreement being seen with benign melanosis (74.5%) and high-grade C-MIL (85.4%). Lowest agreements remained between pathologists for low-grade C-MIL (38.7%). Regarding WHO-EYE05 C-MIL scoring and clinical outcomes, local recurrences of noninvasive lesions developed in 8% and 34% of the low- and high-grade cases. Invasive melanoma only occurred in 47% of the cases that were assessed as high-grade C-MIL. This extensive international collaborative study is the first to undertake a comprehensive review of the WHO-EYE05 C-MIL scoring system, which showed good interobserver agreement and reproducibility.

KW - conjunctival melanoma

KW - conjunctival melanoma in situ

KW - digital pathology

KW - high-grade conjunctival melanocytic intraepithelial lesions

KW - immunohistochemistry

KW - low-grade conjunctival melanocytic intraepithelial lesions

U2 - 10.1016/j.labinv.2023.100281

DO - 10.1016/j.labinv.2023.100281

M3 - Review

C2 - 37924948

AN - SCOPUS:85182956039

VL - 104

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 1

M1 - 100281

ER -

ID: 381236622